Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib plus Capecitabine in PIK3CA mutant mCRC
NCT04753203Phase 2Unknown
- Sponsor
- Korean Cancer Study Group
- Start
- Feb 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alpelisib in metastatic colorectal cancer (mCRC), sponsored by Korean Cancer Study Group. Status: unknown.
02
Drugs
alpelisib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04753203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04753203.